We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Manipulating Ribozymes to Control Gene Activity

By Biotechdaily staff writers
Posted on 12 Oct 2004
A new study explores the use of ribozymes--catalytic RNA that cleaves certain target RNA and thus prohibits gene function--in conjunction with specific drugs to control gene expression as a possible treatment for chronic diseases.

Investigators at Harvard Medical School (Boston, MA, USA) evaluated hundreds of known ribozymes and found two that functioned well in human cells. More...
When the ribozymes were inserted into cells, they shut down gene activity by cleaving RNA and preventing protein synthesis. Next, the investigators searched for drugs that would inhibit ribozyme activity and allow the gene to continue to function. Two likely candidates were found.


To demonstrate how the system could function, the investigators inserted the gene for luciferase along with an embedded ribozyme into the retinas of mice. With no treatment, luciferase was not produced, but after treatment with a ribozyme inhibitor, luciferase could be detected. These findings were published in the September 23, 2004, issue of Nature.

"Perhaps the most exciting aspect of the new work is that, in conjunction with other technologies, we will likely be able to ‘tailor' gene regulation systems to respond to any drug or chemical,” said senior author Dr. Richard Mulligan, professor of genetics at Harvard Medical School. "Ultimately, the system should also enable the ‘release' of a therapeutically useful protein in response to changing concentrations of chemicals in cells. For instance, it may be possible to develop a gene therapy whereby cells are engineered to secrete insulin in response to a rise in glucose. Such ‘biological sensing' could have a wide range of applications.”



Related Links:
Harvard Medical School

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.